Orexo AB (ORX) - Financial and Strategic SWOT Analysis Review

March 2021 | 53 pages | ID: OE1532A6426EN
GlobalData

Abstracts

Orexo AB (ORX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

• Business description – A detailed description of the company’s operations and business divisions.
• Corporate strategy – Analyst’s summarization of the company’s business strategy.
• SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
• Company history – Progression of key events associated with the company.
• Major products and services – A list of major products, services and brands of the company.
• Key competitors – A list of key competitors to the company.
• Key employees – A list of the key executives of the company.
• Executive biographies – A brief summary of the executives’ employment history.
• Key operational heads – A list of personnel heading key departments/functions.
• Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
• Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
• Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Orexo AB (Orexo) is a specialty pharmaceutical company that focuses on the research, formulation, development, registration and commercialization of drugs. The company's commercial product portfolio consists of Abstral, Edluar and Zubsolv. The company employs proprietary drug delivery technologies in the development of its products. It also carries out the industrial-scale production of pharmaceutical products. Orexo collaborates with various pharmaceutical companies to advance and commercialize its products. Orexo is headquartered in Uppsala, Sweden.

Orexo AB Key Recent Developments

Jan 28,2021: Orexo Q4 2020 full year report
Nov 04,2020: Orexo interim report Q3 2020
Sep 25,2020: Orexo Digital Therapeutics business update October 1
Jul 16,2020: Orexo interim report Q2 2020
Jun 17,2020: Orexo and Lyfebulb announce call for digital solutions to treat substance use disorder

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

• The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

• The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

• Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.

• Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

• Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Contents

SECTION 1 - ABOUT THE COMPANY

Orexo AB - Key Facts
Orexo AB - Key Employees
Orexo AB - Key Employee Biographies
Orexo AB - Major Products and Services
Orexo AB - History
Orexo AB - Company Statement
Orexo AB - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries

SECTION 2 – COMPANY ANALYSIS

Company Overview
Orexo AB - Business Description
Business Segment: Digital Therapeutics
Overview
Performance
Business Segment: HQ & Pipeline
Overview
Performance
Business Segment: US Pharma
Overview
Performance
Key Stats
Geographical Segment: Europe and United Kingdom
Performance
Geographical Segment: Rest of the World
Performance
Geographical Segment: The US
Performance
R&D Overview
Orexo AB - Corporate Strategy
Orexo AB - SWOT Analysis
SWOT Analysis - Overview
Orexo AB - Strengths
Orexo AB - Weaknesses
Orexo AB - Opportunities
Orexo AB - Threats
Orexo AB - Key Competitors

SECTION 3 – COMPANY FINANCIAL RATIOS

Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts

SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

Orexo AB, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Orexo AB, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Orexo AB, Recent Deals Summary

SECTION 5 – COMPANY’S RECENT DEVELOPMENTS

Jan 28, 2021: Orexo Q4 2020 full year report
Nov 04, 2020: Orexo interim report Q3 2020
Sep 25, 2020: Orexo Digital Therapeutics business update October
Jul 16, 2020: Orexo interim report Q2 2020
Jun 17, 2020: Orexo and Lyfebulb announce call for digital solutions to treat substance use disorder
Apr 28, 2020: Orexo: interim report Q1 2020
Apr 16, 2020: James Noble appointed as Chairman of the Board
Jan 30, 2020: Q4 incl full year report 2019

SECTION 6 – APPENDIX

Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Orexo AB, Key Facts
Orexo AB, Key Employees
Orexo AB, Key Employee Biographies
Orexo AB, Major Products and Services
Orexo AB, History
Orexo AB, Subsidiaries
Orexo AB, Key Competitors
Orexo AB, Ratios based on current share price
Orexo AB, Annual Ratios
Orexo AB, Annual Ratios (Cont...1)
Orexo AB, Annual Ratios (Cont...2)
Orexo AB, Interim Ratios
Orexo AB, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Orexo AB, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Orexo AB, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List Of Figures

LIST OF FIGURES

Orexo AB, Performance Chart (2016 - 2020)
Orexo AB, Ratio Charts
Orexo AB, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Orexo AB, Pharmaceuticals & Healthcare, Deals by Type, 2015 to YTD 2021